Catalyst calendar
19 upcoming events across 17 companies: 9 with a confirmed date, the rest editorial estimates that can slip by quarters. Filter by company or quarter, then download the selection as an .ics file or subscribe to the full feed.
Q4 2026 4 events
4 November 2026CongressconfirmedSNMMI Theranostics Conference 2026, Bethesda, Maryland (4 to 7 November)SNMMI's conference devoted to theranostics alone: dosimetry practice, alpha-emitter programmes, supply and reimbursement rather than broad nuclear medicine.
Society of Nuclear Medicine and Molecular ImagingRadioligand therapy (beta emitters)Radioligand dosimetryLutetium-177 radioligand therapySource6 November 2026Congressconfirmed65th Annual Meeting of the Korean Society of Nuclear Medicine with the 25th ARCCNM, Seoul (6 to 7 November)Korea's national nuclear medicine meeting, held with the Asian Regional Cooperative Council for Nuclear Medicine. Where Korean radioligand programmes (FutureChem, CellBion) report domestically before Western congresses.
Source19 November 2026Congressconfirmed66th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine, Himeji (19 to 21 November)Japan's national nuclear medicine meeting. Japanese approvals and supply questions (domestic Mo-99 production, PDRadiopharma's product line) are discussed here first.
SourceQ4 2026Deal closingexpectedTempus completes the acquisition of PersonalisAll-stock deal at $16.25 per share announced July 2026; the companies guided to a close in late 2026 or early 2027.
SourceQ1 2027 3 events
4 February 2027CongressconfirmedSNMMI Mid-Winter Meeting 2027, San Francisco (4 to 6 February)The practice-side SNMMI meeting: radiopharmacy operations, dosimetry workshops, regulatory and coding sessions.
Society of Nuclear Medicine and Molecular ImagingRadiopharmaceutical GMP and releasing a drug that decaysRadiopharmacy and cyclotron networksSource11 February 2027CongressconfirmedASCO Genitourinary Cancers Symposium 2027, San Francisco (11 to 13 February)Where PSMA radioligand therapy trials are first presented. The abstracts are deposited as Journal of Clinical Oncology supplements and are harvested by scripts/fetch-abstracts.ts.
NovartisLantheusCuriumMetastatic castration-resistant prostate cancerMetastatic hormone-sensitive prostate cancerLutetium-177 vipivotide tetraxetan177Lu-PSMA-I&TPSMA PETSource11 March 2027Congressconfirmed9th Theranostics World Congress (TWC2027), Osaka (11 to 14 March)Theranostics-only congress with a dedicated targeted alpha therapy track; the 2027 edition is in Japan, which makes it the main meeting point for Asian alpha-emitter programmes.
NovartisBayerFusion Pharmaceuticals (AstraZeneca)AstraZenecaOrano MedRadioMedixRadioligand therapy (beta emitters)Actinium-225 PSMA agents212Pb-DOTAMTATERadioligand dosimetrySourceQ2 2027 2 events
30 April 2027Congressconfirmed57th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine, Gold Coast (30 April to 2 May)Australia and New Zealand's nuclear medicine meeting. Australian developers (Telix, Clarity) and ANSTO's isotope supply report here.
ANSTO (Australian Nuclear Science and Technology Organisation)Clarity PharmaceuticalsTelix PharmaceuticalsSource5 June 2027CongressconfirmedSNMMI Annual Meeting 2027, Washington, DC (5 to 8 June)The largest nuclear medicine meeting in the United States: new tracers, radiochemistry, dosimetry and the year's radioligand trial updates across oncology, cardiology and neurology.
Society of Nuclear Medicine and Molecular ImagingRadioligand therapy (beta emitters)PSMA PETPeptide receptor radionuclide therapy (PRRT)SourceQ4 2027 10 events
11 November 2027Congressconfirmed67th Annual Scientific Meeting of the Japanese Society of Nuclear Medicine, Omiya (11 to 13 November)The 2027 edition of Japan's national nuclear medicine meeting, announced on the society's English meetings page.
Source2027Label or clearance decisionexpectedFDA decision on the Galleri multi-cancer early detection test (premarket approval)Follows the 23 September 2026 advisory committee. PMA decisions typically come months after the panel; no date has been announced.
Source2027Expected readoutexpectedHARMONi-3: ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy, first-line NSCLCThe first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population. Timing is our estimate from the registry record; the sponsor has not given a date.
Source2027Expected readoutexpectedSUNRAY-01: olomorasib plus pembrolizumab, first-line KRAS G12C NSCLCPhase 3 in first-line KRAS G12C-mutant NSCLC. Timing is a registry-based estimate.
Source2027Expected readoutexpectedKrascendo 1: divarasib versus sotorasib or adagrasib, previously treated KRAS G12C NSCLCThe first phase 3 comparing KRAS G12C inhibitors head to head. Timing is a registry-based estimate.
Source2027Expected readoutexpectedIDeate-Lung02: ifinatamab deruxtecan versus chemotherapy, relapsed small-cell lung cancerPivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sankyo collaboration. Timing is a registry-based estimate.
Source2027Expected readoutexpectedREJOICE-Ovarian01: raludotatug deruxtecan in platinum-resistant ovarian cancerPhase 2/3 for the CDH6 ADC. Timing is a registry-based estimate.
Source2027Expected readoutexpectedTROPION-Lung14: datopotamab deruxtecan plus osimertinib, first-line EGFR-mutant NSCLCWould move the TROP2 ADC into the first-line EGFR-mutant setting on top of the standard TKI. Timing is a registry-based estimate.
Source2027Expected readoutexpectedASCENT-07: sacituzumab govitecan versus chemotherapy, first-line HR-positive HER2-negative metastatic breast cancerTests the ADC as the first chemotherapy after endocrine therapy. Timing is a registry-based estimate.
Source2027FilingexpectedRegulatory filings for intismeran autogene plus pembrolizumab in adjuvant melanoma (INTerpath-001)The sponsors said filings would follow the positive topline result of August 2026 and the full data presentation. Timing is our estimate.
Source
How to read this
Confirmed events carry a source that states the date: a PDUFA goal date in a sponsor release, an advisory committee notice, a congress programme. Expected events are our estimate from the registry primary completion date and sponsor statements; treat them as a quarter, not a day.
Companies are attached directly for catalysts and derived for readout-calendar rows from the products named (each product’s companies in the corpus). Past events stay in the data and can be shown with the checkbox.
Calendar feed
Subscribe to /catalysts/feed.ics in Google Calendar, Outlook or Apple Calendar to get every event, including expected ones placed on the first day of their period. The download button exports only the rows you have filtered to.
Missing a catalyst? Add it to src/data/catalysts.ts with company and product ids and a source; congresses and policy dates belong in src/data/calendar.ts.